Paolo Tarantino

Paolo Tarantino: You don’t always need a fancy new drug to impact patients QoL

Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:

”You don’t always need a fancy new drug to impact patients QoL. In the D-TORCH phase 3 trial, the use of topical diclofenac during capecitabine reduced the risk of G2-3 HFS (3.8% vs 15%, p=0.03) and of HFS-related dose reductions. Should be considered SoC.”

Paolo Tarantino: You don’t always need a fancy new drug to impact patients QoL

Read further.
Source: Paolo Tarantino/X

cancer capecitabine ClinicalTrials D-TORCH Diclofenac Hand Foot Syndrome healthcare medicine OncoDaily Oncology Paolo Tarantino Phase 3 Trial quality of life Standard of Care